HIV-related advocacy evaluation training for civil society organisations
Adapted from well-established decision-making concepts and honed through practical application in resource-limited settings, the AFP Advocacy Portfolio includes:
1. Advocate for Family Planning, an introduction to AFP’s approach.
2. Develop a Strategy, featuring a tool to understand your context... and AFP SMART: A Guide to Quick Wins, our 9-step approach to developing a focused, collaborative advocacy strategy that leads to quick wins.
3. Implement a Plan, tools to monitor your impact and make your case to decision makers.
4. Capture Results, with the AFP Results Cascade: A User’s Guide, a monitoring and evaluation tool that provides instructions to track a quick win or series of quick wins to long-term impact, and case study writing guidance.
more
Policy briefs produced for FP2020 and other countries, presenting analysis of Family Planning Effort (FPE) scores from the current and previous rounds. Research and policy implications based on the analyses are also presented.
Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet...ing of GARP in Kathmandu, Nepal in July 2016. In the meeting, this core group was expanded to include other members from different sectors with the selection of the Chair and co-chairs. These were asked to serve on a voluntary basis, in their own individual capacities, with no personal gains, or gains to the institutions to which they are affiliated. The first phase of GARP took place from 2009 to 2011 and involved four countries: India, Kenya, South Africa and Vietnam. Phase one culminated in the 1st Global Forum on Bacterial Infections, held in October 2011 in New Delhi, India. In 2012, phase two of GARP was initiated with the addition of working groups in Mozambique, Tanzania, Nepal and Uganda. Phase three has added Bangladesh, Lao PDR, Nigeria, Pakistan and Zimbabwe to the network to date.
more
In resource restriced countries
Issue Brief no. 16. 20 Sept 2021.
Many studies have shown the effectiveness of vaccination against COVID-19 and that it protects against severe
illness. A high vaccination rate is needed to combat the pandemic worldwide. Due to misinformation and myths,
there is still a great hesitancy to vaccina...te . With this Issue Brief, we would like to present various myths and provide
you with educational materials on the respective topics for communication in the MEDBOX
more
MEDBOX Dossier no. 16. 28 Sept 2021.
De nombreuses études ont montré l'efficacité de la vaccination contre le COVID-19 et le fait qu'elle protège contre les maladies graves.
maladie grave. Un taux de vaccination élevé est nécessaire pour combattre la pandémie dans le monde entier. En raiso...n de la désinformation et des mythes, les gens hésitent encore beaucoup à se faire vacciner. Dans ce dossier, nous souhaitons vous présenter différents mythes et vous fournir du matériel éducatif sur ces sujets et vous fournir du matériel éducatif sur les sujets respectifs à communiquer dans le MEDBOX.
more
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID-19 doses, stimulated new resolve to address future... supply security. In 2021, the AU set a target to produce and supply more than 60% of the vaccine doses on the continent by 2040.
In the last 18 months alone, more than 30 new African manufacturing projects have been announced and estimates indicate that the African vaccine market across all existing and projected novel products could range between US$ 2.8 billion and US$ 5.6 billion by 2040*, demonstrating the potential for a thriving regional industry to emerge.
more